Preclinical News and Research

RSS

Preclinical study: Combination therapy of SPX-106 and D-tagatose reduces triglycerides and cholesterol

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its drug candidate, SPX-106, achieved statistically significant reductions in triglycerides and cholesterol when administered in combination with D-tagatose for nine weeks to genetically engineered mice prone to dyslipidemia.

3 Jun 2011

IMUC, BioWa sign license deal to develop ADCC enhanced antibodies for cancer

ImmunoCellular Therapeutics, Ltd. and BioWa, Inc. today announced that they have entered into a agreement to provide IMUC with access to BioWa's patented POTELLIGENT Technology platform for the development of antibody-dependent cellular cytotoxicity enhanced antibodies.

3 Jun 2011

Study finds notable prevalence of childhood abuse in migraine patients

A notable prevalence of childhood abuse - physical, sexual, verbal, or emotional - in migraine patients has been observed and documented over the last few years. In fact, it has emerged as a significant enough issue for the American Headache Society to devote an entire plenary session to it at its annual scientific conference in Washington this week.

2 Jun 2011

PCF funds 14 new Creativity Awards for advanced prostate cancer research

The Prostate Cancer Foundation today announced that it has funded 14 new Creativity Awards for advanced prostate cancer research. These two-year awards are designed to support innovative research ideas that have the potential to achieve breakthroughs for improved prostate cancer diagnosis and treatment.

2 Jun 2011

Covidien's PCOx mesh receives U.S. FDA 510(k) clearance and European CE Mark approval

Covidien, a leading global provider of healthcare products, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance and the European regulatory authorities have granted the CE Mark to Parietex Optimized Composite mesh.

2 Jun 2011

Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011

Niiki Pharma announced today that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL.

2 Jun 2011

Rochester receives $1M FDA, BDRSA grant to begin first controlled clinical trial in Juvenile Batten disease

After years of building hope for a treatment, Rochester researchers and clinicians will begin the first controlled clinical trial for Juvenile Batten disease this summer, thanks to $1 million in grants from the Food and Drug Administration and the Batten Disease Support and Research Association.

1 Jun 2011

Centocor Ortho Biotech, AVEO sign license deal to develop, commercialize RON-targeted antibodies

AVEO Pharmaceuticals, Inc. today announced it has entered into an exclusive license agreement with Centocor Ortho Biotech Inc. for the worldwide development and commercialization of AVEO's internally-discovered antibodies targeting the RON receptor.

1 Jun 2011

Heptares, AstraZeneca partner to discover and develop new GPCR drug targets

AstraZeneca and Heptares Therapeutics today announced they have entered a four-year collaboration focused on the potential discovery and development of new medicines targeting G-protein coupled receptors.

31 May 2011

Cancer drug helps prevent hypertensive heart disease

A promising cancer treatment drug can restore function of a heart en route to failure from high blood pressure, researchers at UT Southwestern Medical Center have found.

31 May 2011

Study suggests new therapeutic targets for virally-induced asthma attacks

When children with asthma get the flu, they often land in the hospital gasping for air. Researchers at Children's Hospital Boston have found a previously unknown biological pathway explaining why influenza induces asthma attacks.

30 May 2011

Lipidomic profiling can lead to better and earlier prediction of major diseases

Studying the genetic make-up of different varieties of lipids in the blood plasma of an individual can lead to a better and earlier prediction of diseases such as diabetes, atherosclerosis, and heart disease, two researchers will tell the annual conference of the European Society of Human Genetics today.

30 May 2011

NILVAD consortium awarded €6 million grant to develop new Alzheimer's disease treatment

An international research consortium led by Trinity College Dublin that aims to develop a new Alzheimer's disease treatment has just been selected for grant funding of €6 million by the European Commission Seventh Framework Programme (FP7).

27 May 2011

Lactate shuttle also exists in human tumors

Researchers at the Kimmel Cancer Center at Jefferson have shed new light on the longstanding conundrum about what makes a tumor grow-and how to make it stop. Interestingly, cancer cells accelerate the aging of nearby connective tissue cells to cause inflammation, which ultimately provides "fuel" for the tumor to grow and even metastasize.

27 May 2011

4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune and cancer diseases, will present pre-clinical data on vidofludimus - its lead small-molecule drug candidate against autoimmune diseases - in systemic lupus erythematosus at EULAR 2011, Europe's largest scientific conference on rheumatic diseases, in London, UK, from May 25-28, 2011.

27 May 2011

Tacrolimus prevents breast cancer growth in pre-clinical studies

Tacrolimus, a drug that is commonly used to prevent organ transplantation rejection, inhibits breast cancer growth in pre-clinical studies. The finding from UNC scientists was reported in the May 26th PLoS ONE.

27 May 2011

Pro-Pharmaceuticals announces name change to Galectin Therapeutics

Pro-Pharmaceuticals, Inc. today announced that it has changed its name to Galectin Therapeutics Inc. to more accurately reflect the Company's core expertise in galectin science and its leading platform for the creation of galectin inhibitors to treat serious diseases including fibrosis and cancer.

27 May 2011

Medicago, USAMRIID enter research collaboration for Ebola vaccine candidate

Medicago Inc., a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has entered into a research collaboration agreement with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) for the development of a plant-based VLP vaccine candidate for the prevention of Ebola. Ebola is a very serious hemorrhagic fever virus for which no licensed treatment or vaccine exists.

26 May 2011

Lytix Biopharma completes two LTX-109 Phase I/IIa studies in MRSA, Gram+ skin infections

The Norwegian pharmaceutical company Lytix Biopharma today announces the successful completion of two Phase I/IIa studies with the topical antimicrobial drug Lytixar - one for nasal decolonisation of MRSA / MSSA bacteria and one for treatment of Gram+ skin infections.

26 May 2011

Investigators receive NIH grant to help move gene therapy for MPS IIIB toward clinical trials

Investigators at Nationwide Children's have received a grant from the National Institutes of Health to help move a therapy for MPS IIIB that has been shown effective in mice toward clinical trials in humans.

26 May 2011

Preclinical News and Research

Preclinical study: Combination therapy of SPX-106 and D-tagatose reduces triglycerides and cholesterol

IMUC, BioWa sign license deal to develop ADCC enhanced antibodies for cancer

Study finds notable prevalence of childhood abuse in migraine patients

PCF funds 14 new Creativity Awards for advanced prostate cancer research

Covidien's PCOx mesh receives U.S. FDA 510(k) clearance and European CE Mark approval

Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011

Rochester receives $1M FDA, BDRSA grant to begin first controlled clinical trial in Juvenile Batten disease

Centocor Ortho Biotech, AVEO sign license deal to develop, commercialize RON-targeted antibodies

Heptares, AstraZeneca partner to discover and develop new GPCR drug targets

Cancer drug helps prevent hypertensive heart disease

Study suggests new therapeutic targets for virally-induced asthma attacks

Lipidomic profiling can lead to better and earlier prediction of major diseases

NILVAD consortium awarded €6 million grant to develop new Alzheimer's disease treatment

Lactate shuttle also exists in human tumors

4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011

Tacrolimus prevents breast cancer growth in pre-clinical studies

Pro-Pharmaceuticals announces name change to Galectin Therapeutics

Medicago, USAMRIID enter research collaboration for Ebola vaccine candidate

Lytix Biopharma completes two LTX-109 Phase I/IIa studies in MRSA, Gram+ skin infections

Investigators receive NIH grant to help move gene therapy for MPS IIIB toward clinical trials

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics